Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants
with relapsed or refractory MCL.
The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg
daily) of PCI-32765 in this population.